Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Profit After Tax: 2014-2025

Historic Profit After Tax for vTv Therapeutics (VTVT) over the last 12 years, with Sep 2025 value amounting to -$10.3 million.

  • vTv Therapeutics' Profit After Tax fell 77.14% to -$10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.4 million, marking a year-over-year decrease of 24.97%. This contributed to the annual value of -$22.7 million for FY2024, which is 12.56% up from last year.
  • Latest data reveals that vTv Therapeutics reported Profit After Tax of -$10.3 million as of Q3 2025, which was down 40.18% from -$7.4 million recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' Profit After Tax ranged from a high of -$841,000 in Q2 2021 and a low of -$10.3 million during Q3 2025.
  • Over the past 3 years, vTv Therapeutics' median Profit After Tax value was -$6.2 million (recorded in 2025), while the average stood at -$6.6 million.
  • Over the last 5 years, vTv Therapeutics' Profit After Tax had its largest YoY gain of 83.15% in 2021, and its largest YoY loss of 690.11% in 2021.
  • vTv Therapeutics' Profit After Tax (Quarterly) stood at -$9.5 million in 2021, then skyrocketed by 35.78% to -$6.1 million in 2022, then grew by 27.08% to -$4.4 million in 2023, then increased by 0.09% to -$4.4 million in 2024, then tumbled by 77.14% to -$10.3 million in 2025.
  • Its Profit After Tax stands at -$10.3 million for Q3 2025, versus -$7.4 million for Q2 2025 and -$6.2 million for Q1 2025.